Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HRMY with free AI briefings, catalyst countdowns, and dilution alerts.

HRMY · Harmony Biosciences Holdings, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$771.1M Cash on Hand
CF+ Cash Runway
Follow HRMY by email Get an email when HRMY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HRMY, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2027-04-01 Pitolisant GR narcolepsy NDA 66% ±30% by Apr 16

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What HRMY Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Pitolisant
FDA approved Aug 2019 · Wakix
Restless Legs Syndrome Phase 4 · NCT05581576 Unknown
Clemizole HCl Lennox Gastaut Syndrome Phase 3 · NCT05066217 Recruiting
ZYN002 Fragile X Syndrome Phase 3 · NCT04977986 Completed
Open-label Pitolisant Idiopathic Hypersomnia Phase 3 · NCT05156047 Completed
HBS-301 Idiopathic Hypersomnia Phase 3 · NCT07500090 Recruiting
Double-blind Pitolisant Idiopathic Hypersomnia Phase 3 · NCT05156047 Completed
Quadrivalent Inactivated Influenza Vaccine Influenza Phase 2 · NCT05284799 Completed
OVX836 480µg Influenza Phase 2 · NCT05284799 Completed
OVX836 shot Vaccine-Preventable Diseases Phase 2 · NCT06582277 Completed
Part 1 Drug Interaction Phase 1 · NCT06930872 Completed
Bupropion Drug Drug Interaction Phase 1 · NCT07824193 Completed
pitolisant delayed-release (DR) Healthy Participants Phase 1 · NCT07860736 Completed
Part 2 Drug Interaction Phase 1 · NCT06930872 Completed
Clemizole Healthy Participants Phase 1 · NCT07879170 Recruiting
MV-LASV Lassa Virus Infection Phase 1 · NCT04055454 Completed
Moxifloxacin Healthy Participants Phase 1 · NCT07879170 Recruiting

Also used in these trials (approved or third-party drugs, not HRMY's own candidates): Phenytoin, Omeprazole, Midazolam Hydrochloride, Itraconazole, Modafinil.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HRMY holds $771.1M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 8 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HRMY files for a raise →

👥 Who Owns HRMY

Insiders 0.1% Institutions (488 holders) 99.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 7,361,888 12.54% 2026-09-30
American Century Investment Management, Institution (13G, 5%+) 3,113,418 5.30% 2026-09-30
FMR LLC Institution (13G, 5%+) 3,112,812 5.30% 2025-12-31
Vanguard Portfolio Management Institution (13G, 5%+) 2,943,383 5.01% 2026-06-30
Sandip Kapadia
CHIEF FINANCIAL OFFICER · +241,775 options
Insider 24,521 0.04% 2026-01-26
Valor IV Pharma Holdings, LLC
10% owner
Insider 23,714 0.04% 2025-08-28
Kumar Budur
CHIEF MEDICAL OFFICER · +136,194 options
Insider 13,115 0.02% 2026-09-16
Jeffrey M. Dayno
PRESIDENT, CEO, Director · +223,600 options
Insider 7,346 0.01% 2026-01-22
Adam H. Zaeske
CHIEF COMMERCIAL OFFICER · +164,400 options
Insider 4,327 0.01% 2026-04-07
Stephen M. Mollichella
INT PRINCIAL FINANCIAL OFFICER
Insider 2,506 0.00% 2026-07-16
Andrew Serafin
CHIEF STRATEGY OFFICER · +50,400 options
Insider 1,474 0.00% 2026-01-22

Share count 58,723,199 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HRMY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HRMY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.